The next phase of personalized medicine in epilepsy may be therapy that is tested and targeted to the specific genetic mutation causing an individual’s seizure disorder.
A new genetic research company is the first to pair expertise in rare disease genomics with advanced analytics to provide healthcare professionals with an extensive and highly personalized evaluation on individual epilepsy patients.
Medscape Medical News spoke to Pairnomix CEO Matthew Fox during the American Epilepsy Society (AES) 69th Annual Meeting to discuss this new initiative.
According to Fox, no other company is providing this kind of precision medicine in epilepsy. The aim, he explained, is to help patients who have already been diagnosed with epilepsy and have undergone sequencing.
Scientists then replicate the mutation that has been identified, characterize it, and test drugs on it.
“Individuals who have a rare mutation that is causing their seizures in the epilepsy setting, who have nowhere to go once their mutation has been identified, can now contact us,” said Fox.
“We will take that mutation into a laboratory setting and create a replica of it. We will characterize the mutation, and we will test compounds against the mutation that might restore activity to normal.”
The company then reports this information back to the treating physician, who will ultimately make the treatment decisions along with the patient.
An estimated 2% to 4% of childhood epilepsies are genetically based. Researchers are discovering more genetic causes of epilepsies all the time.
Pairnomix’s advisory board has many heavyweights in the field of genetics, neurology, and electrophysiology. One member is epilepsy expert Orrin Devinsky, MD, professor, neurology, and director, New York University Comprehensive Epilepsy Center.
Dr Devinsky says the advantage of this new initiative is that it incorporates a targeted approach to epilepsy therapy that accelerates the process of finding an effective therapy.
Once an initial model is developed with the specific gene of interest, “multiple drugs can be screened that might be predicted to work.” For example, if a channel disorder is identified, specific calcium channel inhibitors could be tested.
If there are promising results here, the drug or drugs would then be further tested on a mouse model, he said.
The drugs that will be tested in these models will have human safety data, stressed Dr Devinsky. “We will not be taking a drug off the shelf that has never been given to a human before; because even if works, it would be so hard to get it to a patient.”
The number of epilepsy treatment options is “in the hundreds” now, he said.
Cost a Sticking Point
Fox acknowledged that initially the testing will be costly — prohibitively so for most patients — because building cell lines is extremely expensive. He pointed out, though, that many patients and families have already spent “hundreds of thousands of dollars” over time for academic universities and genetic counselors, in most cases coming up without an effective therapy.
“Our only sticking point is obviously the high price at the outset is prohibitive for many,” he said. “We will make all efforts to move toward the insurance system and reduce our costs as much as possible over time.”
To that end, the company is committed to doing up to $300,000 in pro bono work to support up to four patient reviews. It has signed a partnership with KCNQ2 Cure Alliance to explore rare genetic mutations in KCNQ2 epileptic encephalopathy, with the goal of identifying more effective and accurately targeted therapies.
Although the company will initially offer this personalized approach to patients with epilepsy, it plans to eventually expand to include other rare diseases.
Attracting interest from large pharmaceutical companies for this type of venture is difficult; for the most part, they’re focused more on developing drugs that will target groups, albeit in some cases small ones, rather than individuals, said Fox. “We are helping individuals from the bottom up.”
But not all epilepsy experts are so keen.
“The big question is whether this Pairnomix initiative is ready for prime time,” newly named AES president, Michael Privitera, MD, professor, and director, Epilepsy Center, University of Cincinnati Neuroscience Institute, Ohio, told Medscape Medical News.
Dr Privitera said he has “issues” with companies doing “very expensive genomic testing without proof that it actually has benefits.”
He pointed out that he attended a Hot Topics session during the AES meeting here, where Annapurna Poduri, MD, director, Epilepsy Genetics Program, Boston Children’s Hospital, Massachusetts, showed a list of genetic tests in which the results would potentially lead to changes in therapy. “That list was very short,” said Dr Privitera.
Mr Fox is the CEO of Pairnomix. Dr Devinsky is on the advisory board of Pairnomix. Dr Privitera has no relationship to the company.
American Epilepsy Society (AES) 69th Annual Meeting.